ArticleScientific reports2025
Deciphering the role of crucial miRNAs involved in diabetic cardiomyopathy through a multiomics approach.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Diabetic cardiomyopathy: a comprehensive review of diagnosis, management, and future directions.Diabetology & metabolic syndrome · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Conventional drug discovery routes take decades to identify critical gene signatures involved in a disease. Though in silico platforms and software have simplified the process by reducing the time and energy needed to arrive at significant molecular targets for disease conditions, they are not accessible to everyone. Here, we propose a systematic strategic protocol to identify critical players in the disease pathogenesis using the vast amount of molecular omics data available on various public domains, setting diabetic cardiomyopathy as the case study. We use databases like KEGG, DisGeNET, HMDD, and literature to curate the key genes and miRNAs associated with the disease. We analysed 395 genes and 20 miRNAs for our analysis. Critical pathways like the insulin resistance pathway, the AGE-RAGE pathway, and the PI3K-AKT-mTOR pathway were enriched in our analysis through the Metascape platform. A protein-protein interaction network was generated using the STRING database. The export of this network to the Cytoscape platform helped to identify the clusters, node interactions, and hub genes. Our approach finally identified hsa-miR-302a-3p as the critical miRNA that regulates the highest-ranked hub gene, AKT1. This systematic methodology lays a solid foundation for the identification of critical therapeutic targets for any disease condition, thereby increasing the success rate for further stages of development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.